Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q4 EPS of ($0.07), $4.58 worse than the analyst estimate of $4.51. Revenue for the quarter came in at $972.13 million versus the consensus estimate of $975.18 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2023 EPS of $16.90-$17.86, versus the consensus of $18.00. Jazz Pharmaceuticals sees FY2023 revenue of $3.675-3.875 billion, versus the consensus of $3.76 billion.